gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2021-31-5-61-65gastro-j-650Research ArticleНАЦИОНАЛЬНАЯ ШКОЛА ГАСТРОЭНТЕРОЛОГИИ, ГЕПАТОЛОГИИNATIONAL COLLEGE OF GASTROENTEROLOGY, HEPATOLOGYСовременные возможности применения растительного препарата STW 5 в лечении функциональных заболеваний желудочно-кишечного трактаCurrent Prospects of Herbal STW 5 Agent in Treatment of Functional Gastrointestinal Diseaseshttps://orcid.org/0000-0002-1395-9566ШептулинА. А.SheptulinA. A.

Шептулин Аркадий Александрович — доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифосовского

119435, г. Москва, ул. Погодинская ул., д. 1, стр. 1

Arkadiy A. Sheptulin — Dr. Sci. (Med.), Prof., Department of Internal Disease Propaedeutics, Gastroenterology and Hepatology, Sklifosovsky Institute of Clinical Medicine

119435, Moscow, Pogodinskaya str. 1, bld. 1

 

arkalshep@gmail.comФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияSechenov First Moscow State Medical University (Sechenov University)Russian Federation2021020120223156165Copyright © Шептулин А.А., 20222022Шептулин А.А.Sheptulin A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/650Цель обзора

Цель обзора: показать современные возможности применения растительного препарата STW 5 (Иберогаст®) в лечении функциональных заболеваний желудочно-кишечного тракта (ЖКТ).

Основные положения

Основные положения. Недостаточная эффективность лечения наиболее распространенных функциональных заболеваний ЖКТ — функциональной диспепсии (ФД) и синдрома раздраженного кишечника (СРК) — обусловливается многофакторностью их патогенеза. Между тем большинство препаратов, применяющихся для их лечения, действуют лишь на отдельные патогенетические звенья данных заболеваний. Это ставит на повестку дня задачу поиска препарата, обладающего мультитаргетным действием. Таким препаратом является Иберогаст®, оказывающий влияние на различные звенья патогенеза ФД и СРК. В статье рассматриваются механизмы действия Иберогаста® и оценивается эффективность его применения при лечении ФД и СРК.

Заключение

Заключение: результаты проведенных исследований показывают, что Иберогаст® является эффективным и безопасным препаратом для лечения ФД и СРК.

Aim

Aim. A review of current therapeutic perspectives of the herbal STW 5 medicine (Iberogast®) in functional gastrointestinal (GI) diseases.

Key points

Key points. A limited remediation in most common functional GI diseases, functional dyspepsia (FD) and irritable bowel syndrome (IBS), is conditioned by their multifactorial pathogenesis. Meanwhile, most specific medicines only target selected pathogenesis components, thus warranting a multitarget agent development. Such is Iberogast® that acts at variant components of FD and IBS pathogenesis. The article reviews the Iberogast® mechanisms of action and evaluates its treatment efficacy in FD and IBS.

Conclusion

Conclusion. The current evidence claims that Iberogast® provides an effective and safe treatment for FD and IBS.

 

 

функциональная диспепсиясиндром раздраженного кишечникаИберогаст®functional dyspepsiairritable bowel syndromeIberogast®Публикация подготовлена при поддержке компании БайерThe publication was supported by A/O BayerReferencesStanghellini V., Chan F.K.L., Hasler W.L., Malagelada J.R., Suzuki H., Tack J., Talley N.J. Gastroduodenal disorders. Gastroenterology. 2016; 150 (6): 1380–92. DOI: 10.1053/j.gastro.2016.02.011Stanghellini V., Chan F.K.L., Hasler W.L., Malagelada J.R., Suzuki H., Tack J., Talley N.J. Gastroduodenal disorders. Gastroenterology. 2016; 150 (6): 1380–92. DOI: 10.1053/j.gastro.2016.02.011Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R. Bowel disorders. Gastroenterology. 2016;150(6):1393–407. DOI: 10.1053/j.gastro.2016.02.031Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R. Bowel disorders. Gastroenterology. 2016;150(6):1393–407. DOI: 10.1053/j.gastro.2016.02.031Шептулин А.А., Кардашева С.С., Курбатова А.А. Сочетание функциональной диспепсии и синдрома раздраженного кишечника: случайная комбинация или закономерная связь? Клиническая медицина. 2020;98(4):251–5. DOI: 10.30629/0023-2149-2020-98-4-251-255Sheptulin A.A., Kardasheva S.S., Kurbatova A.A. The overlap of functional dyspepsia and irritable bowel syndrome: a random combitation or appropriate relationship? Klinicheskaya Meditsina. 2020;98(4):251–5 DOI: 10.30629/0023-2149-2020-98-4-251-255 (In Russ.)Allescher H.-D., Burgell R., Malfertheiner P., Mearin F. Multi-target treatment for irritable bowel syndrtome with STW 5: pharmacological modes of action. J Gastrointestin Liver Dis. 2020;29(2):227–33. DOI: 10.15403/jgld-814Allescher H.-D., Burgell R., Malfertheiner P., Mearin F. Multi-target treatment for irritable bowel syndrtome with STW 5: pharmacological modes of action. J Gastrointestin Liver Dis. 2020;29(2):227–33. DOI: 10.15403/jgld-814Allescher H.-D., Abdel-Aziz H. Mechanism of action of STW5 in functional dyspepsia and IBS: the origin of multi-target. Dig Dis. 2017;35(suppl. 1):18–24. DOI: 10.1159/000485456Allescher H.-D., Abdel-Aziz H. Mechanism of action of STW5 in functional dyspepsia and IBS: the origin of multi-target. Dig Dis. 2017;35(suppl. 1):18–24. DOI: 10.1159/000485456Malfertheiner P. STW5 (Iberogast) therapy in gastrointestinal functional disorders. Dig Dis. 2017;35(suppl. 1):25–9. DOI: 10.1159/000485410Malfertheiner P. STW5 (Iberogast) therapy in gastrointestinal functional disorders. Dig Dis. 2017;35(suppl. 1):25–9. DOI: 10.1159/000485410Simmen U., Kelber O., Okpanyi S.N., et al. Bimding of STW 5 (Iberogast® ) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors Phytomedicine. 2006;13(suppl. 5):51–5. DOI: 10.1016/j.phymed.2006.03.012Simmen U., Kelber O., Okpanyi S.N., et al. Bimding of STW 5 (Iberogast® ) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors Phytomedicine. 2006;13(suppl. 5):51–5. DOI: 10.1016/j.phymed.2006.03.012Khayyal M.T., El-Ghazaly M.A., Kenawy S., Seif-ElNasr M., Mahran L.G. Fafafi Y.A., et al. Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Arzneim Forsch Drug Res. 2001;51(7):545–53. DOI: 10.1055/s-0031-1300078Khayyal M.T., El-Ghazaly M.A., Kenawy S., Seif-ElNasr M., Mahran L.G. Fafafi Y.A., et al. Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Arzneim Forsch Drug Res. 2001;51(7):545–53. DOI: 10.1055/s-0031-1300078Hohenester B., Rühl A., Kelber O., Schemann M. The herbal preparation STW5 (Iberogast® ) has potent and region-specific effects on gastric motility. Neurogastroenterol Motil. 2004;16(6):765–73. DOI: 10.1111/j.1365-2982.2004.00648.xHohenester B., Rühl A., Kelber O., Schemann M. The herbal preparation STW5 (Iberogast® ) has potent and region-specific effects on gastric motility. Neurogastroenterol Motil. 2004;16(6):765–73. DOI: 10.1111/j.1365-2982.2004.00648.xSchemann M., Michel K., Zeller F., Hohenester B., Rühl A. Region-specific effects of STW 5 (Iberogast® ) and its components in gastric fundus, corpus and antrum. Phytomedicine. 2006;13(suppl. 5):90–9. DOI: 10.1016/j.phymed.2006.03.020Schemann M., Michel K., Zeller F., Hohenester B., Rühl A. Region-specific effects of STW 5 (Iberogast® ) and its components in gastric fundus, corpus and antrum. Phytomedicine. 2006;13(suppl. 5):90–9. DOI: 10.1016/j.phymed.2006.03.020Pilichiewicz A.N., Horowitz M., Russo A., Maddox A., Jones K.L., Schemann M., et al. Effects of Iberogast® on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Amer J Gastroenterol. 2007;102(6):1276–83. DOI: 10.1111/j.1572-0241.2007.01142.xPilichiewicz A.N., Horowitz M., Russo A., Maddox A., Jones K.L., Schemann M., et al. Effects of Iberogast® on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Amer J Gastroenterol. 2007;102(6):1276–83. DOI: 10.1111/j.1572-0241.2007.01142.xMadisch A., Vinson B. Abdel-Aziz H., Kelber O., Nieber K., Kraft K., Storr M. Modulation of gastrointestinal motility beyond metoclopramide and domperidone: Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders. Wien Med Wochenschr. 2017;167(7–8):160–8. DOI: 10.1007/s10354-017-0557-3Madisch A., Vinson B. Abdel-Aziz H., Kelber O., Nieber K., Kraft K., Storr M. Modulation of gastrointestinal motility beyond metoclopramide and domperidone: Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders. Wien Med Wochenschr. 2017;167(7–8):160–8. DOI: 10.1007/s10354-017-0557-3Ammon H.P.T., Lelber O., Okpanyi S.N. Spasmolytic and tonic effect of Iberogast (STW 5) in intestinal smooth muscle. Phytomedicine. 2006;13(suppl. 5):67–74. DOI: 10.1016/j.phymed.2006.08.004Ammon H.P.T., Lelber O., Okpanyi S.N. Spasmolytic and tonic effect of Iberogast (STW 5) in intestinal smooth muscle. Phytomedicine. 2006;13(suppl. 5):67–74. DOI: 10.1016/j.phymed.2006.08.004Liu C.-Y., Müller M.H., Glatzle J., Weiser D., Kelber O., Enck P., et al. The herbal preparation STW5 (Iberogast) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil. 2004;16(6):759–64. DOI: 10.1111/j.1365-2982-2004.00576.xLiu C.-Y., Müller M.H., Glatzle J., Weiser D., Kelber O., Enck P., et al. The herbal preparation STW5 (Iberogast) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil. 2004;16(6):759–64. DOI: 10.1111/j.1365-2982-2004.00576.xMichael S., Kelber O., Нauschildt S., Spanel-Borowski K., Nieber K. Inhibition of inflammation-induced alterations in rat small intestine by the herbal preparations STW5 and STW6. Phytomedicine. 2009;16:161–71. DOI: 10.1016/j.phymed.2008.10.011Michael S., Kelber O., Нauschildt S., Spanel-Borowski K., Nieber K. Inhibition of inflammation-induced alterations in rat small intestine by the herbal preparations STW5 and STW6. Phytomedicine. 2009;16:161–71. DOI: 10.1016/j.phymed.2008.10.011Wadie W., Abdel-Aziz H., Zaki H.F., Kelber O., Weiser D., Khayyal T. STW5 is effective in dextran sulfate sodium-induced colitis in rats. Int J Colorectal Dis. 2012;27(11):1445–53. DOI: 10.1007/s00384-012-1473-zWadie W., Abdel-Aziz H., Zaki H.F., Kelber O., Weiser D., Khayyal T. STW5 is effective in dextran sulfate sodium-induced colitis in rats. Int J Colorectal Dis. 2012;27(11):1445–53. DOI: 10.1007/s00384-012-1473-zVon Arnim U., Peitz U., Vinson B., Gundermann KJ, Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol. 2007;102(6):1268– 75. DOI: 10.1111/j.1572-0241.2006.01183.xVon Arnim U., Peitz U., Vinson B., Gundermann KJ, Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol. 2007;102(6):1268– 75. DOI: 10.1111/j.1572-0241.2006.01183.xBraden B., Caspary W., Bȍrner N., Vinson B., Schneider A.R. Clinical effects of STW 5 Iberogast® are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterol Motil. 2009;21(6):632–9. DOI: 10.1111/j.1365-2982.2008.01249.xBraden B., Caspary W., Bȍrner N., Vinson B., Schneider A.R. Clinical effects of STW 5 Iberogast® are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterol Motil. 2009;21(6):632–9. DOI: 10.1111/j.1365-2982.2008.01249.xBuchert D. Wirksamkeit und Verträglichkeit von Iberogast® bei Patienten mit gesicherter Non Ulkus Dyspepsie. Z Phytotherapie. 1994;15:45–6.Buchert D. Wirksamkeit und Verträglichkeit von Iberogast® bei Patienten mit gesicherter Non Ulkus Dyspepsie. Z Phytotherapie. 1994;15:45–6.Madisch A., Melderis H., Mayr G., Sassin I., Hotz J. Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie. Z Gastroenterologie. 2001;39(7):1–8. DOI: 10.1055/s-2001-1614Madisch A., Melderis H., Mayr G., Sassin I., Hotz J. Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie. Z Gastroenterologie. 2001;39(7):1–8. DOI: 10.1055/s-2001-1614Gundermann K.-J., Godehardt E., Ulbrich M. Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized clinical trials. Adv Ther. 2003;20(1):1–7. DOI: 10.10077/BF02850118Gundermann K.-J., Godehardt E., Ulbrich M. Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized clinical trials. Adv Ther. 2003;20(1):1–7. DOI: 10.10077/BF02850118Holtmann G., Nandurkar S., Talley N.J. Herbal medicine for the treatment of functional dyspepsia: a systematic review of the literature and meta-analysis. Gastroenterology. 2007;132(suppl. 2):Abstract W1204.Holtmann G., Nandurkar S., Talley N.J. Herbal medicine for the treatment of functional dyspepsia: a systematic review of the literature and meta-analysis. Gastroenterology. 2007;132(suppl. 2):Abstract W1204.Melzer J., Rȍsch W., Reichling J., Brignoli R., Saller R. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast® ). Aliment Pharmacol Ther. 2004;20(11–12):1279–87. DOI: 10.1111/j.1365-2036.2004.02275Melzer J., Rȍsch W., Reichling J., Brignoli R., Saller R. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast® ). Aliment Pharmacol Ther. 2004;20(11–12):1279–87. DOI: 10.1111/j.1365-2036.2004.02275Raedsch R., Hanisch J., Bock P., Sibaev A., Vinson B., Gunderman K.J. Wirksamkeit und Unbedenklichkeit des Phytopharmacons STW 5 versus Metoclopramid bei Funktioneller Dyspepsie unter Praxisbedingungen — eine retrolektive Kohortenstudie. Z Gastroenterol. 2007;45(10):1041–8. DOI: 10.1055/s-20070963357Raedsch R., Hanisch J., Bock P., Sibaev A., Vinson B., Gunderman K.J. Wirksamkeit und Unbedenklichkeit des Phytopharmacons STW 5 versus Metoclopramid bei Funktioneller Dyspepsie unter Praxisbedingungen — eine retrolektive Kohortenstudie. Z Gastroenterol. 2007;45(10):1041–8. DOI: 10.1055/s-20070963357Madisch A., Holtmann G., Plein K., Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multicentre trial. Alement Pharmacol Ther. 2004;19(3):271–9. DOI: 10.1111/j.1365-2036.2004/01859Madisch A., Holtmann G., Plein K., Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multicentre trial. Alement Pharmacol Ther. 2004;19(3):271–9. DOI: 10.1111/j.1365-2036.2004/01859Sassin I., Buchert D. Efficacy and tolerability of the herbal preparation Iberogast in the therapy of functional dyspepsia. Phytomedicine. 2000;7(suppl. 2):91–2.Sassin I., Buchert D. Efficacy and tolerability of the herbal preparation Iberogast in the therapy of functional dyspepsia. Phytomedicine. 2000;7(suppl. 2):91–2.Klein-Galczinsky C., Sassin I. Anwendungsbeobachtung zur Wirksamkeit und Verträglichkeitvon Iberogast in der Therapie des Colon irritable. Phytotherapie an der Schwelle zun neuen Jahrtausend. 1999;125:Abstract P25.Klein-Galczinsky C., Sassin I. Anwendungsbeobachtung zur Wirksamkeit und Verträglichkeitvon Iberogast in der Therapie des Colon irritable. Phytotherapie an der Schwelle zun neuen Jahrtausend. 1999;125:Abstract P25.Abdel-Aziz H., Kelber O., Lorkowski G., Storr M. Evaluating the multitarget effects of combinations through multistep clustering of pharmacological data: the example of the commercial preparation Iberogast. Planta Medica. 2017;83(14–15):1130–46. DOI: 10.1055/s-0043-116852Abdel-Aziz H., Kelber O., Lorkowski G., Storr M. Evaluating the multitarget effects of combinations through multistep clustering of pharmacological data: the example of the commercial preparation Iberogast. Planta Medica. 2017;83(14–15):1130–46. DOI: 10.1055/s-0043-116852Layer P., Andresen V., Pehl C., Allescher H., Bischoff S.C., Classen M., et al. Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Joint guideline of the German Society for digestive and metabolic diseases (DGVS) and the German Society for Neurgastroenterology and Motility (DGNM). Z Gastroenterol. 2011;49(2):237–93.Layer P., Andresen V., Pehl C., Allescher H., Bischoff S.C., Classen M., et al. Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Joint guideline of the German Society for digestive and metabolic diseases (DGVS) and the German Society for Neurgastroenterology and Motility (DGNM). Z Gastroenterol. 2011;49(2):237–93.Lapina T.L., Trukhmanov A.S. Herbal preparation STW 5 for functional gastrointestinal disorders: clinical experience in everyday practice. Dig Dis. 2017;35(suppl. 1):30– 5. DOI: 10.1159/000485411Lapina T.L., Trukhmanov A.S. Herbal preparation STW 5 for functional gastrointestinal disorders: clinical experience in everyday practice. Dig Dis. 2017;35(suppl. 1):30– 5. DOI: 10.1159/000485411Gundermann K.-J., Vinson B., Hänicke S. Die funktionelle Dyspepsie bei Kindern — eine retrospective Studie mit einem Phytopharmakon. Pädiatrie. 2004;10:1–6.Gundermann K.-J., Vinson B., Hänicke S. Die funktionelle Dyspepsie bei Kindern — eine retrospective Studie mit einem Phytopharmakon. Pädiatrie. 2004;10:1–6.Vinson B.R., Radke M. The herbal preparation STW 5 for the treatment of functional gastrointestinal diseases in children aged 3–14 years — a prospective non interventional study Digestive Disease Week, Chicago. 2011:Abstract #523. Gastroenterology. 2011;140(5):S102. DOI: 10.1016/S0016-5085(11)60415-0Vinson B.R., Radke M. The herbal preparation STW 5 for the treatment of functional gastrointestinal diseases in children aged 3–14 years — a prospective non interventional study Digestive Disease Week, Chicago. 2011:Abstract #523. Gastroenterology. 2011;140(5):S102. DOI: 10.1016/S0016-5085(11)60415-0Ottilinger B., Storr M., Malfertheiner P., Allescher H.-D. STW 5 (Iberogast) — a safe and effective standart in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr. 2013;163(3–4):65–72. DOI: 10.1007/s10354-012-0169-xOttilinger B., Storr M., Malfertheiner P., Allescher H.-D. STW 5 (Iberogast) — a safe and effective standart in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr. 2013;163(3–4):65–72. DOI: 10.1007/s10354-012-0169-x

The authors declare that there are no conflicts of interest present.